KCA
Search
- Page Path
- HOME > Search
Original Article
- Gastrointestinal cancer
- Tumor Control and Overall Survival after Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer: A Meta-Analysis
- Hoon Sik Choi, Bae Kwon Jeong, Ki Mun Kang, Hojin Jeong, Jin Ho Song, In Bong Ha, Oh-Young Kwon
- Cancer Res Treat. 2020;52(4):1188-1198. Published online July 21, 2020
- DOI: https://doi.org/10.4143/crt.2020.402
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
In pulmonary oligometastases from colorectal cancer (POM-CRC), the primarily recommended local therapy is metastasectomy. Stereotactic body radiotherapy (SBRT) is another local therapy modality that is considered as an alternative option in patients who cannot undergo surgery. The purpose of this meta-analysis is to demonstrate the effects of SBRT on POM-CRC by integrating the relevant studies.
Materials and Methods
The authors explored MEDLINE, EMBASE, Cochrane Library, Web of Science, and SCOPUS, and selected studies including patients treated with SBRT for POM-CRC and availability of local control (LC) or overall survival (OS) rate. In this meta-analysis, the effect of SBRT was presented in the form of the LC and OS rates for 1, 2, 3, and 5 years after SBRT as pooled estimates, and the frequency of pulmonary toxicity of grade 3 or higher after SBRT (PTG3-SBRT).
Results
Fourteen full texts among the searched 4,984 studies were the objects of this meta-analysis. The overall number of POM-CRC patients was 495 as per the integration of 14 studies. The pooled estimate LC rate at 1, 2, 3, and 5 years after SBRT was 81.0%, 71.5%, 56.0%, and 61.8%, and the OS rate was 86.9%, 70.1%, 57.9%, and 43.0%, respectively. The LC and OS rates gradually declined until 3 years after SBRT in a similar pattern. Among the 14 studies, only two studies reported PTG3-SBRT as 2.2% and 10.8%, respectively.
Conclusion
For POM-CRC, SBRT is an ablative therapy with a benefit on LC and OS rates and less adverse effects on the lung. -
Citations
Citations to this article as recorded by
- Therapeutic approaches to pulmonary metastases in colorectal cancer
I. Yu. Kokhanovskaia, A. S. Fatyanova, E. A. Tarabrin, I. V. Reshetov
Research and Practical Medicine Journal.2025; 12(3): 61. CrossRef - Treatment of Colorectal Lung Metastases: Two Centers Retrospective Study
Myrtle F. Krul, Jan M. van Rees, Amihan M. de Boer, Karlijn K. Neve, Cornelis Verhoef, Koert F.D. Kuhlmann, Tarik R. Baetens, Tineke E. Buffart, Joost L. Knegjens, Houke M. Klomp, Theo J.M. Ruers, Marianne de Vries, Joost Rothbarth, Esther van Meerten, Jo
Digestive Diseases.2024; 42(6): 538. CrossRef - Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study
Emmanuel Mesny, Myriam Ayadi, Pauline Dupuis, Guillaume Beldjoudi, Ronan Tanguy, Isabelle Martel-Lafay
Radiation Oncology.2023;[Epub] CrossRef - Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
Davide Franceschini, Maria Ausilia Teriaca, Luca Dominici, Ciro Franzese, Marta Scorsetti
Cancer Management and Research.2021; Volume 13: 7009. CrossRef
- Therapeutic approaches to pulmonary metastases in colorectal cancer
- 12,026 View
- 174 Download
- 14 Web of Science
- 4 Crossref
First
Prev
